Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding

Hepato-Gastroenterology

Volumn 50, Issue 51, 2003, Pages 889-892

  Fujitani, Kazumasa ^a   Tsujinaka, Toshimasa ^a   Hirao, Motohiro ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Gastric cancer; Oral 5 fluorouracil derivative; Peritoneal; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BILIRUBIN; FLUOROURACIL DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; FEMALE; FOLLOW UP; GASTRECTOMY; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LYMPH NODE METASTASIS; MALE; NAUSEA; PATIENT COMPLIANCE; PERITONEUM METASTASIS; PIGMENT DISORDER; POSTOPERATIVE CARE; PRIORITY JOURNAL; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM SEEDING; NEOPLASM STAGING; OXONIC ACID; PERITONEAL NEOPLASMS; PYRIDINES; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 0038577350     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-557.
2. Tatsumi K, Fukushima M, Shirasaka T, Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res (Gann) 1987; 78:748-755.
3. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53:4004-4009.
4. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999; 57:202-210.
5. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
6. Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000; 58:191-197.
7. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA,Krook JE, Mailliard JA, Tschetter LK: Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994; 12:412-416.
8. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K, Kurihara M: Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994; 30A:2091-2093.
9. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71:3813-3818.
10. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10:541-548.
11. Louvet C, Gramont A, Demuynck B, Nordlinger B, Maisani JE, Lagadec B, Delfau S, Varette C, Canali GG, Krulik M: High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. Ann Oncol 1991; 2:229-230.
12. Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K: Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 1994; 168:36-40.
13. Sugarbaker PH, Yonemura Y: Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000; 58:96-107.
14. NCI Common Toxicity Criteria. Bethesda, MD, National Cancer Institute, Division of Cancer Treatment, 1988.
15. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition-. Gatric Cancer 1998; 1:10-24.
16. Noh SH, Yoo CH, Chung HC, Roh JK, Shin DW, Min JS: Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. Oncology 2001; 60:24-30.
17. Yonemura Y, Fujimura T, Fushida S, Fujita H, Bando E, Nishimura G, Miwa K, Endou Y, Tanaka M, Sasaki T: A new surgical approach (peritonectomy) for the treatment of peritoneal dissemination. Hepatogastroenterology 1999; 46:601-609
18. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T: Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85:529-534.
19. Yu W, Whang I, Averbach A, Chang D, Sugarbaker PH: Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. Am Surgeon 1998; 64:1104-1108.